$SKYE
Skye Bioscience, Inc. Stock $skye

$skye Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-Q Financial Statement

#000164033419002291 Filed on November 14, 2019

Income Statement

Concept	2019 Q4	2019 Q3	2018 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.128M	$990.1K	$1.080M
YoY Change	4.41%	1.03%	17.39%
% of Gross Profit
Research & Development	$715.9K	$513.0K	$240.0K
YoY Change	198.3%	662.37%	242.86%
% of Gross Profit
Depreciation & Amortization	$360.00	$1.100K	$0.00
YoY Change
% of Gross Profit
Operating Expenses	$1.844M	$1.503M	$1.320M
YoY Change	39.66%	43.75%	33.33%
Operating Profit		-$1.503M
YoY Change		43.75%
Interest Expense	$7.421M	$301.5K	-$4.910M
YoY Change	-251.14%		-1463.89%
% of Operating Profit
Other Income/Expense, Net		-$3.428M
YoY Change		226.25%
Pretax Income	$4.852M	-$4.931M	-$6.220M
YoY Change	-178.01%	135.22%	887.3%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income	0.0%
Net Earnings	$4.852M	-$4.931M	-$6.220M
YoY Change	-178.01%	135.22%	547.92%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.04
Diluted Earnings Per Share	$34.18K	-$0.04	-$11.73
COMMON SHARES
Basic Shares Outstanding	134.1M shares	133.0M shares
Diluted Shares Outstanding		133.0M shares

Balance Sheet

Concept	2019 Q4	2019 Q3	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.830M	$1.319M	$1.850M
YoY Change	-1.08%	24.47%	611.54%
Cash & Equivalents	$1.830M	$1.319M	$1.853M
Short-Term Investments
Other Short-Term Assets	$7.550K	$3.375K	$2.609K
YoY Change	189.38%	-96.93%	-99.1%
Inventory
Prepaid Expenses	$152.7K	$395.4K	$93.19K
Receivables
Other Receivables
Total Short-Term Assets	$1.995M	$1.723M	$1.954M
YoY Change	2.1%	48.51%	248.87%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.983K	$2.349K	$3.445K
YoY Change	-42.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.983K	$2.349K	$3.445K
YoY Change	-42.44%	-76.51%
TOTAL ASSETS
Total Short-Term Assets	$1.995M	$1.723M	$1.954M
Total Long-Term Assets	$1.983K	$2.349K	$3.445K
Total Assets	$1.997M	$1.725M	$1.957M
YoY Change	2.02%	47.44%	249.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$129.8K	$206.9K	$15.60K
YoY Change	732.27%	244.88%	-84.4%
Accrued Expenses	$77.94K		$180.0K
YoY Change	-56.7%		-10.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$970.8K	$14.26M	$15.94M
YoY Change	-93.91%	26.0%	1867.77%
LONG-TERM LIABILITIES
Long-Term Debt	$387.1K	$3.296M	$1.360M
YoY Change	-71.54%
Other Long-Term Liabilities	$90.80K	$567.6K	$220.0K
YoY Change	-58.73%		-60.0%
Total Long-Term Liabilities	$477.9K	$3.864M	$1.580M
YoY Change	-69.76%		186.58%
TOTAL LIABILITIES
Total Short-Term Liabilities	$970.8K	$14.26M	$15.94M
Total Long-Term Liabilities	$477.9K	$3.864M	$1.580M
Total Liabilities	$1.449M	$18.13M	$17.52M
YoY Change	-91.73%	60.14%	1188.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$32.17M	-$37.03M	-$33.23M
YoY Change	-3.17%
Common Stock	$32.72M	$20.62M	$17.66M
YoY Change	85.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$548.1K	-$16.40M	-$15.56M
YoY Change
Total Liabilities & Shareholders Equity	$1.997M	$1.725M	$1.957M
YoY Change	2.02%	47.44%	249.49%

Cashflow Statement

Concept	2019 Q4	2019 Q3	2018 Q4
OPERATING ACTIVITIES
Net Income	$4.852M	-$4.931M	-$6.220M
YoY Change	-178.01%	135.22%	547.92%
Depreciation, Depletion And Amortization	$360.00	$1.100K	$0.00
YoY Change
Cash From Operating Activities	-$1.503M	-$4.525M	-$1.010M
YoY Change	48.83%	451.79%	-52.13%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00	$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.014M	3.991M	1.810M
YoY Change	11.26%		-23.95%
NET CHANGE
Cash From Operating Activities	-1.503M	-4.525M	-1.010M
Cash From Investing Activities	0.000	0.000	0.000
Cash From Financing Activities	2.014M	3.991M	1.810M
Net Change In Cash	510.6K	-534.0K	800.0K
YoY Change	-36.17%	-34.88%	220.0%
FREE CASH FLOW
Cash From Operating Activities	-$1.503M	-$4.525M	-$1.010M
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	-$1.503M	-$4.525M	-$1.010M
YoY Change	48.83%	451.79%	-52.58%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	4512	USD
CY2019Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	395441	USD
CY2018Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	93193	USD
CY2019Q3	us-gaap	Other Assets Current OtherAssetsCurrent	3375	USD
CY2018Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	184461	USD
CY2019Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	13737783	USD
CY2018Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	15738913	USD
CY2017Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	271715	USD
CY2018Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	11110567	USD
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	14263643	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15938971	USD
CY2019Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	3296249	USD
CY2018Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	1360960	USD
CY2019Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	567606	USD
CY2017Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	551322	USD
CY2018Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2019Q3	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1319360	USD
	dei	Entity Central Index Key EntityCentralIndexKey	0001516551
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1853373	USD
CY2019Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	4512	USD
CY2018Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2609	USD
CY2019Q3	us-gaap	Assets Current AssetsCurrent	1722688	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	1953687	USD
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2349	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3445	USD
CY2019Q3	us-gaap	Assets Assets	1725037	USD
CY2018Q4	us-gaap	Assets Assets	1957132	USD
CY2019Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	206930	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	15597	USD
CY2019Q3	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	318930	USD
	dei	Document Type DocumentType	10-Q
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Small Business EntitySmallBusiness	true
CY2019Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	134095247	shares
	dei	Document Period End Date DocumentPeriodEndDate	2019-09-30
	dei	Entity Registrant Name EntityRegistrantName	Emerald Bioscience, Inc.
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1503114	USD
CY2018Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	219453	USD
CY2018Q3	embi	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	1050729	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	990110	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	1503114	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	301547	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	67291	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	1045620	USD
CY2019Q3	us-gaap	Liabilities Liabilities	18127498	USD
CY2018Q4	us-gaap	Liabilities Liabilities	17519384	USD
CY2019Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2019Q3	us-gaap	Common Stock Value CommonStockValue	134095	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	133908	USD
CY2019Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	20488778	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	17528947	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-37025334	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33225107	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	-16402461	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-15562252	USD
	us-gaap	Depreciation Depreciation	1096	USD
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1725037	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1957132	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	513004	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1045620	USD
	us-gaap	Depreciation Depreciation	1178	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	514683	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	484720	USD
	embi	Fair Value Adjustment Of Derivative Liabilities FairValueAdjustmentOfDerivativeLiabilities	2024660	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	978329	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	302248	USD
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	134095247	shares
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	134095247	shares
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	134095247	shares
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	133001746	shares
CY2018Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	131445057	shares
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	133001746	shares
CY2018Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	131445057	shares
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	134095247	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-3569506	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	-5753979	USD
	embi	Fair Value Of Derivative Liability Excess Of Proceeds FairValueOfDerivativeLiabilityExcessOfProceeds	322644	USD
	embi	Fair Value Of Derivative Liability Excess Of Proceeds FairValueOfDerivativeLiabilityExcessOfProceeds	7174634	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	34608	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	-8245279	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	-10155120	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	-27864191	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	-11641442	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1522031	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	92291	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3267037	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3284880	USD
	us-gaap	Operating Expenses OperatingExpenses	4789068	USD
	us-gaap	Operating Expenses OperatingExpenses	3377171	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4789068	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3377171	USD
CY2019Q3	embi	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	3126464	USD
	embi	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	-2024660	USD
	embi	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	1653477	USD
	embi	Fair Value Of Warrant Liability In Excess Of Proceeds FairValueOfWarrantLiabilityInExcessOfProceeds	-322644	USD
	embi	Fair Value Of Warrant Liability In Excess Of Proceeds FairValueOfWarrantLiabilityInExcessOfProceeds	-7174634	USD
	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	137192	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-590392	USD
	us-gaap	Interest Expense InterestExpense	711575	USD
	us-gaap	Interest Expense InterestExpense	37708	USD
CY2018Q3	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Income Other InterestIncomeOther	74	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3428011	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1050729	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	990441	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9593329	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4931125	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2096349	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3798627	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12970500	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1600	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1642	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-4931125	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-2096349	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3800227	USD
	us-gaap	Net Income Loss NetIncomeLoss	-12972142	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-8213793	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-2662000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-14774392	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	15905290	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	132885675	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	117434563	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	167690989	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	117434563	shares
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-804	USD
CY2019Q3	us-gaap	Share Based Compensation ShareBasedCompensation	170106	USD
CY2018Q3	us-gaap	Share Based Compensation ShareBasedCompensation	154508	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-55418	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	191333	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-48407	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4524712	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2928857	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3731799	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-534013	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	798557	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1857885	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	264383	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1323872	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1062940	USD
	embi	Cash And Cash Equivalents CashAndCashEquivalents	1319360	USD
	embi	Cash And Cash Equivalents CashAndCashEquivalents	1058438	USD
	embi	Supplemental Restricted Cash SupplementalRestrictedCash	4512	USD
	embi	Supplemental Restricted Cash SupplementalRestrictedCash	4502	USD
	embi	Total Cash Equivalents And Restricted Cash Shown In Consolidated TotalCashEquivalentsAndRestrictedCashShownInConsolidated	1323872	USD
	embi	Total Cash Equivalents And Restricted Cash Shown In Consolidated TotalCashEquivalentsAndRestrictedCashShownInConsolidated	1062940	USD
CY2019Q3	embi	Working Capital Deficit WorkingCapitalDeficit	-12540955	USD
	embi	Fair Value Adjustment Of Derivative Liabilities FairValueAdjustmentOfDerivativeLiabilities	-1653477	USD
	us-gaap	Increase Decrease In Notes Payable Related Parties Current IncreaseDecreaseInNotesPayableRelatedPartiesCurrent	15000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	134469	USD
	us-gaap	Interest Paid Net InterestPaidNet	272611	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	438964	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4385	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4385	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	16901	USD
	embi	Warrants Vested And Outstanding WarrantsVestedAndOutstanding	57943250	shares
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-194906	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	766	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	2609	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3233099	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	98700	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	400000	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	9301	USD
	embi	Proceeds From Convertible Multi Draw Credit Agreement ProceedsFromConvertibleMultiDrawCreditAgreement	3990699	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3990699	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1600	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1642	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1947227	USD
	embi	Conversion Of Outstanding Preferred Stock Subject To Redemption Into Common Stock ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock	828916	USD
	embi	Exercise Of Warrants ExerciseOfWarrants	144375	USD
	embi	Exercise Of Warrants ExerciseOfWarrants	1333866	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1710000	USD
	embi	Fair Value Of Warrants Issued In Connection With Financings FairValueOfWarrantsIssuedInConnectionWithFinancings	10424634	USD
	embi	Proceeds Allocated To Equity Classified Warrants Issued With Convertible Multi Draw Credit Agreement ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement	716110	USD
	embi	Fair Value Of Compound Derivative Liability Issued With Convertible Multi Draw Credit Agreement FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement	193414	USD
	embi	Beneficial Conversion Feature On Convertible Multi Draw Credit Agreement BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement	1584850	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	229609	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	100603	USD
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	154508	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	171493	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	173084	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	170106	USD
CY2018Q1	embi	Share Issuance Costs ShareIssuanceCosts	16900	USD
CY2018Q2	embi	Share Issuance Costs ShareIssuanceCosts	7778	USD
CY2018Q1	embi	Conversion Of Preferred Stock Series And Conversion Liability Into Common Stock Value ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue	828915	USD
CY2018Q1	embi	Conversion Of Series D Preferred Stock To Common Stock ConversionOfSeriesDPreferredStockToCommonStock	169447	USD
CY2018Q1	embi	Conversion Of Series F Preferred Stock To Common Stock Value ConversionOfSeriesFPreferredStockToCommonStockValue	1777781	USD
CY2018Q1	embi	Conversion Of Secured Convertible Promissory Note Related Party And Accrued Interest ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest	1700878	USD
CY2018Q1	embi	Stock Issued During Period Value Series B Warrant Exercises StockIssuedDuringPeriodValueSeriesBWarrantExercises	1322690	USD
CY2018Q2	embi	Stock Issued During Period Value Series B Warrant Exercises StockIssuedDuringPeriodValueSeriesBWarrantExercises	77875	USD
CY2018Q3	embi	Stock Issued During Period Value Series B Warrant Exercises StockIssuedDuringPeriodValueSeriesBWarrantExercises	32000	USD
CY2019Q2	embi	Stock Issued During Period Value Series B Warrant Exercises StockIssuedDuringPeriodValueSeriesBWarrantExercises	144375	USD
CY2018Q2	embi	Common Stock Issuance Costs CommonStockIssuanceCosts	-7778	USD
CY2019Q1	embi	Warrants Issued In Connection With Convertible Multi Draw Credit Agreement Related Party Value WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue	716110	USD
CY2019Q1	embi	Beneficial Conversion Feature In Connection With Convertible Multi Draw Credit Agreement Related Party Value BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue	1584850	USD
	us-gaap	Use Of Estimates UseOfEstimates	<p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><i>Use of Estimates</i></strong></span></span></p><p style="MARGIN:0px"> </p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The preparation of the Unaudited Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense and equity securities, derivative liabilities and debt with embedded features.</span></span></p>
CY2019Q3	us-gaap	Line Of Credit Facility Fair Value Of Amount Outstanding LineOfCreditFacilityFairValueOfAmountOutstanding	8247319	USD
CY2019Q3	embi	Convertible Multi Draw Credit Facility ConvertibleMultiDrawCreditFacility	3296249	USD
CY2019Q3	embi	Net Loss Available To Common Shareholders Adjusted As Appropriate For Gains Or Losses From Dilutive Securities NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities	-4931125	USD
CY2018Q3	embi	Net Loss Available To Common Shareholders Adjusted As Appropriate For Gains Or Losses From Dilutive Securities NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities	-2096349	USD
	embi	Net Loss Available To Common Shareholders Adjusted As Appropriate For Gains Or Losses From Dilutive Securities NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities	-12972142	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2024660	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1653477	USD
CY2018Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	15958366	USD
CY2019Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	14305389	USD
CY2017Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	823037	USD
CY2018Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	11110567	USD
	embi	Fair Value Of Warrants Issued FairValueOfWarrantsIssued	516058	USD
	embi	Fair Value Of Warrants Issued FairValueOfWarrantsIssued	10784634	USD
	embi	Reclassification Of Derivatives To Equity ReclassificationOfDerivativesToEquity	-144375	USD
	embi	Reclassification Of Derivatives To Equity ReclassificationOfDerivativesToEquity	-2150581	USD
CY2019Q3	embi	Coupon Interest Expense CouponInterestExpense	107334	USD
CY2018Q3	embi	Coupon Interest Expense CouponInterestExpense	0	USD
	embi	Coupon Interest Expense CouponInterestExpense	272611	USD
	embi	Coupon Interest Expense CouponInterestExpense	3100	USD
CY2019Q3	embi	Amortization Of Debt Discount AmortizationOfDebtDiscount	190886	USD
CY2018Q3	embi	Amortization Of Debt Discount AmortizationOfDebtDiscount	0	USD
	embi	Amortization Of Debt Discount AmortizationOfDebtDiscount	429355	USD
	embi	Amortization Of Debt Discount AmortizationOfDebtDiscount	34608	USD
CY2019Q3	embi	Amortization Of Transaction Costs AmortizationOfTransactionCosts	3327	USD
CY2018Q3	embi	Amortization Of Transaction Costs AmortizationOfTransactionCosts	0	USD
	embi	Amortization Of Transaction Costs AmortizationOfTransactionCosts	9609	USD
	embi	Amortization Of Transaction Costs AmortizationOfTransactionCosts	0	USD
	embi	Emerald Financing Issuance Costs EmeraldFinancingIssuanceCosts	154092	USD
	us-gaap	Payments Of Derivative Issuance Costs PaymentsOfDerivativeIssuanceCosts	137192	USD
	embi	Reduction To Additional Paid In Capital From The Issuance Of Common Stock ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock	16900	USD
CY2019Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	478442	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P0Y11M26D
CY2019Q3	embi	Annual Maintenance Fee Payable AnnualMaintenanceFeePayable	75000	USD
CY2017Q2	embi	Monthly Fee MonthlyFee	10000	USD
	embi	Monthly Fee MonthlyFee	20000	USD
CY2018Q3	embi	Total Expense Incurred Under Agreement TotalExpenseIncurredUnderAgreement	0	USD
	embi	Total Expense Incurred Under Agreement TotalExpenseIncurredUnderAgreement	220000	USD

Files In Submission

Name	View Source	Status
0001640334-19-002291-index-headers.html	Edgar Link	pending
0001640334-19-002291-index.html	Edgar Link	pending
0001640334-19-002291.txt	Edgar Link	pending
0001640334-19-002291-xbrl.zip	Edgar Link	pending
embi-20190930.xml	Edgar Link	completed
embi-20190930.xsd	Edgar Link	pending
embi-20190930_cal.xml	Edgar Link	unprocessable
embi-20190930_def.xml	Edgar Link	unprocessable
embi-20190930_lab.xml	Edgar Link	unprocessable
embi-20190930_pre.xml	Edgar Link	unprocessable
embi_10q.htm	Edgar Link	pending
embi_ex103.htm	Edgar Link	pending
embi_ex103img1.jpg	Edgar Link	pending
embi_ex311.htm	Edgar Link	pending
embi_ex312.htm	Edgar Link	pending
embi_ex321.htm	Edgar Link	pending
embi_ex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SKYE
Skye Bioscience, Inc. Stock $skye

2019 Q4 Form 10-Q Financial Statement

#000164033419002291 Filed on November 14, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SKYE Skye Bioscience, Inc. Stock $skye

2019 Q4 Form 10-Q Financial Statement

#000164033419002291 Filed on November 14, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SKYE
Skye Bioscience, Inc. Stock $skye